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Modulation of Methyl Group Metabolism by Streptozotocin-induced
Diabetes and All-trans-retinoic Acid
Abstract
The hepatic enzyme glycine N-methyltransferase (GNMT) plays a major role in the control of methyl group
and homocysteine metabolism. Because disruption of these vital pathways is associated with numerous
pathologies, understanding GNMT control is important for evaluating methyl group regulation. Recently,
gluconeogenic conditions have been shown to modulate homocysteine metabolism and treatment with
glucocorticoids and/or all-trans-retinoic acid (RA)-induced active GNMT protein, thereby leading to methyl
group loss. This study was conducted to determine the effect of diabetes, alone and in combination with RA,
on GNMT regulation. Diabetes and RA increased GNMT activity 87 and 148%, respectively. Moreover, the
induction of GNMT activity by diabetes and RA was reflected in its abundance. Cell culture studies
demonstrated that pretreatment with insulin prevented GNMT induction by both RA and dexamethasone.
There was a significant decline in homocysteine concentrations in diabetic rats, owing in part to a 38%
increase in the abundance of the transsulfuration enzyme cystathionine β-synthase; treatment of diabetic rats
with RA prevented cystathionine β-synthase induction. A diabetic state also increased the activity of the
folate-independent homocysteine remethylation enzyme betaine-homocysteine S-methyltransferase, whereas
the activity of the folate-dependent enzyme methionine synthase was diminished 52%. In contrast, RA
treatment attenuated the streptozotocin-mediated increase in betaine-homocysteine S-methyltransferase,
whereas methionine synthase activity remained diminished. These results indicate that both a diabetic
condition and RA treatment have marked effects on the metabolism of methyl groups and homocysteine, a
finding that may have significant implications for diabetics and their potential sensitivity to retinoids.
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The hepatic enzyme glycine N-methyltransferase
(GNMT) plays a major role in the control of methyl
group and homocysteine metabolism. Because disrup-
tion of these vital pathways is associated with numerous
pathologies, understanding GNMT control is important
for evaluating methyl group regulation. Recently, glu-
coneogenic conditions have been shown to modulate
homocysteine metabolism and treatment with glucocor-
ticoids and/or all-trans-retinoic acid (RA)-induced ac-
tive GNMT protein, thereby leading to methyl group
loss. This study was conducted to determine the effect of
diabetes, alone and in combination with RA, on GNMT
regulation. Diabetes and RA increased GNMT activity 87
and 148%, respectively. Moreover, the induction of
GNMT activity by diabetes and RA was reflected in its
abundance. Cell culture studies demonstrated that pre-
treatment with insulin prevented GNMT induction by
both RA and dexamethasone. There was a significant
decline in homocysteine concentrations in diabetic rats,
owing in part to a 38% increase in the abundance of the
transsulfuration enzyme cystathionine -synthase;
treatment of diabetic rats with RA prevented cystathi-
onine -synthase induction. A diabetic state also in-
creased the activity of the folate-independent homocys-
teine remethylation enzyme betaine-homocysteine
S-methyltransferase, whereas the activity of the folate-
dependent enzymemethionine synthase was diminished
52%. In contrast, RA treatment attenuated the strepto-
zotocin-mediated increase in betaine-homocysteine S-
methyltransferase, whereas methionine synthase activ-
ity remained diminished. These results indicate that
both a diabetic condition and RA treatment have
marked effects on the metabolism of methyl groups and
homocysteine, a finding that may have significant impli-
cations for diabetics and their potential sensitivity to
retinoids.
Methyl group and folate-dependent one-carbon metabolism
are interrelated pathways that provide for the subsequent
transmethylation of various molecules using S-adenosylmethi-
onine (AdoMet)1 (1). An adequate supply of methyl groups via
the diet or the folate-dependent one-carbon pool and regulation
of these pathways are essential in preventing associated pa-
thologies such as cancer, vascular disease, and neural tube
defects (2–4). Glycine N-methyltransferase (GNMT) (EC
2.1.1.20) is an abundant, tissue-specific protein that plays a
key role in the regulation of hepatic methyl group metabolism
by the enzymatic conversion of glycine and AdoMet to S-adeno-
sylhomocysteine (AdoHcy) and sarcosine (1, 5, 6). GNMT func-
tions to optimize the AdoMet/AdoHcy ratio, an indicator of
transmethylation potential, because AdoHcy is a potent inhib-
itor of most AdoMet-dependent methyltransferases (5, 7). Fol-
lowing hydrolysis of AdoHcy, the resulting homocysteine can
undergo remethylation to methionine or be irreversibly catab-
olized by the transsulfuration pathway. Folate-dependent rem-
ethylation occurs with the donation of a methyl group by
5-methyltetrahydrofolate (5-CH3-THF) through the action of
B12-dependent methionine synthase (MS) (8). In hepatic tissue,
betaine derived from the oxidation of choline can also serve as
a folate-independent source of methyl groups for homocysteine
remethylation via the enzyme betaine-homocysteine S-methyl-
transferase (BHMT). Transsulfuration to cysteine occurs
through the activity of two vitamin B6-dependent enzymes,
cystathionine -synthase (CBS) and -cystathionase.
The regulation of hepatic GNMT represents an important
mechanism for controlling both the folate-dependent supply of
methyl groups as well as their utilization in AdoMet-dependent
transmethylation reactions. GNMT activity is regulated in re-
sponse to changes in methyl group status as the result of
allosteric inhibition of 5,10-methylenetetrahydrofolate reduc-
tase by AdoMet (9, 10) and inhibition of GNMT by 5-CH3-THF
(11, 12), the enzymatic product of 5,10-methylenetetrahydrofo-
late reductase. This allows methyl groups to be conserved un-
der conditions of deficiency by decreasing GNMT activity,
whereas elevations in its activity function to dispose of excess
methyl groups. In addition to allosteric control, phosphoryla-
tion of GNMT represents another posttranslational mechanism
to increase the activity of GNMT and regulate methyl group
metabolism (12).
Recent studies have identified both nutritional and hormo-
nal factors that alter methyl group metabolism by targeting the
key enzymes involved. All-trans-retinoic acid (RA) has been
shown to induce hepatic GNMT activity and protein abun-
dance, resulting in the loss of methyl groups for subsequent
transmethylation reactions (13–16). Moreover, dexamethasone
* This work was supported in part by the Iowa Agriculture and Home
Economics Experiment Station, the Iowa State University Office of
Biotechnology, United States Department of Agriculture Grant NRI
01-35200-9854 (to K. L. S.), American Institute for Cancer Research
Grant 00B078REV (to K. L. S.), the American Diabetes Association (to
K. L. S.), and National Institutes of Health Grant DK52501 (to
T. A. G.). The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
§ Both authors contributed equally to this work.
 To whom correspondence should be addressed: Dept. of Food Science
and Human Nutrition, Iowa State University, 220 MacKay Hall, Ames,
IA 50011. Tel.: 515-294-9230; Fax: 515-294-6193; E-mail: kschalin@
iastate.edu.
1 The abbreviations used are: AdoMet, S-adenosylmethionine;
GNMT, glycine N-methyltransferase; AdoHcy, S-adenosylhomocys-
teine; 5-CH3-THF, 5-methyltetrahydrofolate; MS, methionine synthase;
BHMT, betaine-homocysteine S-methyltransferase; CBS, cystathionine
-synthase; RA, all-trans-retinoic acid; DEX, dexamethasone; STZ,
streptozotocin; HPLC, high pressure liquid chromatography.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 44, Issue of October 29, pp. 45708–45712, 2004
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org45708
 at IO
W
A
 STA
TE U
N
IV
 on February 20, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(DEX) was just as effective as RA in the induction of GNMT
activity in rat liver and hepatoma cells, and the co-administra-
tion of both DEX and RA induced GNMT in an additive fashion
(17). A diabetic state characterized by insufficient circulating
concentrations of insulin and elevated levels of the counter-
regulatory hormones glucagon and glucocorticoids has also
been reported to alter enzymes involved in methyl group me-
tabolism. An elevation in the activity of GNMT has been re-
ported in alloxan-induced diabetic sheep and rats (6, 18); how-
ever, little is known about the mechanistic basis for this
increase. Brosnan and co-workers have shown that under dia-
betic conditions, the catabolism of homocysteine was enhanced
by transcriptional regulation of CBS, and these changes were
prevented by treatment with insulin (19–21). Although we
have shown that DEX can significantly alter methyl group and
homocysteine metabolism (17), the focus in this study was to
evaluate these pathways in a diabetic rat model, alone and in
combination with RA, as well as determine the effect of insulin
on preventing these alterations.
EXPERIMENTAL PROCEDURES
Chemicals—Reagents were obtained as follows: S-adenosyl-L-[meth-
yl-3H]methionine, PerkinElmer Life Sciences; chemiluminescence
Western blotting detection reagents, Amersham Biosciences; S-adeno-
syl-L-methionine and streptozotocin, Sigma; protease inhibitors and
RA, Calbiochem; goat anti-mouse IgG horseradish peroxidase, goat
anti-rabbit IgG horseradish peroxidase, and rabbit anti-sheep IgG
horseradish peroxidase, Southern Biotechnology (Birmingham, AL).
GNMT and CBS antibodies were kindly provided by Yi-Ming Chen,
National Yang-Ming University, Taipei, Taiwan (22), and Jan Kraus,
University of Colorado Health Sciences Center, Denver, CO, respec-
tively. All other chemicals were of analytical grade.
Animals—All animal experiments were approved by and conducted
in accordance with Iowa State University Laboratory Animal Resources
Guidelines. Male Sprague-Dawley rats (Harlan Sprague-Dawley, Indi-
anapolis, IN) (125–149 g) were housed in individual plastic cages in a
room with a 12-h light/dark cycle and allowed free access to food and
water. Rats were randomly assigned to treatment groups (6 rats per
group) and acclimated to the control diet (17) for 5 days. Following the
acclimation period, rats received a single intraperitoneal injection of
either streptozotocin (STZ, 60 mg/kg body weight) in the vehicle (10 mM
citrate buffer, pH 4.5) or the vehicle alone. The following day animals
received a daily oral dose of RA (30 mol/kg body weight) or vehicle
(corn oil) alone. Following a 5-day treatment period with RA, rats were
anesthetized and whole blood samples were collected via cardiac punc-
ture. An aliquot of whole blood was used to assess blood glucose con-
centrations using a commercial kit (Sigma), whereas the remaining
blood was centrifuged at 4,000  g for 6 min, and the resulting plasma
fraction was stored at 20 °C for subsequent analysis of homocysteine
concentrations. Liver samples were removed and homogenized in 4
volumes of ice-cold phosphate-buffered (10 mM, pH 7.0) sucrose (0.25 M)
containing 1 mM EDTA, 1 mM sodium azide, and 0.1 mM phenylmeth-
ylsulfonyl fluoride. Following centrifugation at 20,000  g for 30 min,
supernatants were stored at 70 °C with 1 mM -mercaptoethanol for
subsequent enzymatic and protein abundance measurements. Total
soluble protein concentrations were determined based on the method of
Bradford (23) using a commercial kit (Coomassie Plus, Pierce) and
bovine serum albumin as a standard. Additional liver samples were
homogenized in 2 volumes of 0.4 M perchloric acid for the determination
of AdoMet and AdoHcy.
Cell Culture—Rat pancreatic AR42J and hepatoma H4IIE cells were
obtained from the American Type Culture Collection (Manassas, VA).
All cells were grown in 150-cm2 flasks in a humidified incubator with
5% CO2 and a temperature of 37 °C until they were 70–75% confluent.
H4IIE cells were cultured in minimum essential medium containing
10% fetal bovine serum, penicillin (100 units/ml), and streptomycin (0.1
mg/ml). AR42J cells were grown in F-12K nutrient mixture containing
20% fetal bovine serum as well as penicillin and streptomycin. Cell lines
received fresh media prior to the initiation of any treatments. H4IIE
and AR42J cells were treated with either a vehicle of 0.01% dimethyl
sulfoxide (Me2SO, control), 10 M RA, 0.1 M DEX, or both RA and DEX
as described previously (17). A parallel group of AR42J and H4IIE cells
was preincubated with 100 nM insulin for 24 h prior to the addition of
RA and/or DEX. Following a 72-h incubation period, cells were detached
using 0.25% trypsin/1 mM EDTA, washed with Hanks’ balanced salt
solution, and lysed on ice in a buffer containing 10 mM HEPES (pH 7.4),
10 mM sodium pyrophosphate, 50 mM sodium fluoride, 50 mM -glycer-
ophosphate, 5 mM EDTA, 1 mM sodium orthovanadate, 2 mM benzami-
dine, 100 g/ml leupeptin and pepstatin, 250 g/ml soybean trypsin
inhibitor, 0.2 mM phenylmethylsulfonyl fluoride, 24 g/ml p-nitrogua-
nidinobenzoate, and 0.5% Nonidet P-40. Following centrifugation at
16,000  g for 8 min, supernatants were stored at 70 °C for analysis
of GNMT protein abundance.
GNMT Activity Analysis—The enzymatic activity of GNMT was de-
termined using the method described by Cook and Wagner (24) with
minor modifications, and performed in triplicate. The assay mixture
(100 l) consisted of 0.1 M Tris buffer (pH 9.0), 1 mM glycine, 5 mM
dithiothreitol, 1 mM S-adenosyl-L-[methyl-3H]methionine, and was ini-
tiated with 250 g of protein followed by incubation at 25 °C for 30 min.
Trichloroacetic acid (10%) was added to terminate the reaction followed
by the addition of activated charcoal and centrifugation (14,000  g) to
remove radiolabeled AdoMet. Aliquots of the supernatants were re-
moved for liquid scintillation counting.
Determination of GNMT and CBS Protein Abundance—GNMT pro-
tein abundance was determined using immunoblotting techniques as
previously described (17). A 10–20% gradient SDS-polyacrylamide
gel was used to quantify the 32-kDa monomer subunit of GNMT.
Following separation, proteins were transferred to a nitrocellulose
membrane and incubated overnight at 4 °C with a 1:4,000 dilution of
the monoclonal GNMT antibody (22). The membrane was then incu-
bated with goat anti-mouse IgG horseradish peroxidase secondary
antibody for 1 h at room temperature. CBS protein abundance was
analyzed using a similar method as described above to separate the
63-kDa CBS subunit. A 1:20,000 dilution of the polyclonal CBS anti-
body was used, which was followed by incubation with a goat anti-
rabbit IgG horseradish peroxidase secondary antibody. GNMT and
CBS protein abundance were detected with chemiluminescence and
exposed to Kodak X-Omat AR film. Densitometric analysis was per-
formed using SigmaGel software (SPSS, Chicago, IL). For both
GNMT and CBS, three samples from each treatment group were
randomly chosen for analysis on a single immunoblot.
Determination of Hepatic AdoMet and AdoHcy Concentrations—Per-
chloric acid homogenates were centrifuged at 9,000  g for 10 min, and
the resulting supernatants were neutralized and applied to a Sep-Pak
C18 cartridge (Waters Associates, Milford, MA) to obtain AdoMet and
AdoHcy (25, 26). AdoMet and AdoHcy were separated and quantified by
reversed-phase HPLC and UV detection (254 nm) using a mobile phase
containing 30%methanol in 5 mM octane sulfonic acid (pH 4.0) operated
isocratically at 1.2 ml/min.
Analysis of BHMT and MS Activity—BHMT activity was measured
as described previously by Garrow (27). The standard BHMT assay
contained 5 mM DL-homocysteine, 2 mM betaine (0.1 Ci), and 40 g of
total protein. The activity of MS was determined as described previ-
ously (28). The assay reaction mixture containing sodium phosphate
buffer (500 mM, pH 7.5), cyanocobalamin (1.3 M), dithiothreitol (1 M),
AdoMet (10 mM), -mercaptoethanol (82.4 mM), homocysteine (100 mM),
and [methyl-14C]-THF (15 mM, 0.17 Ci/mol) was added to liver su-
pernatants and incubated for 1 h at 37 °C. Ice-cold water was added to
terminate the reaction, and the assay mixture was immediately applied
to a AG 1-X8 (chloride form) resin columns. Effluent fractions (3 ml of
deionized water) were collected for subsequent liquid scintillation
counting. For both the BHMT and MS assay, homocysteine was pre-
pared fresh daily from a thiolactone derivative.
Plasma Homocysteine Analysis—Total plasma homocysteine concen-
trations were determined using HPLC and fluorescence detection (29).
For derivatization, 10% tributylphosphine in dimethylformamide was
added to 300 l of plasma samples and subsequently incubated at 4 °C
for 30 min. The reaction was terminated with ice-cold trichloroacetic
acid containing 1 mM EDTA. Following centrifugation at 1,000  g for
5 min, supernatants were added to a solution containing borate buffer
(0.125 M, pH 9.5), sodium hydroxide (1.55 M), and 4-fluoro-7-sulfoben-
zofurazan (ammonium salt, 0.1%). N-Acetylcysteine (1 mM) was added
to the plasma samples prior to derivatization as an internal standard.
Samples were injected onto a Bondapak C18 Radial-Pak column (Wa-
ters Associates) equilibrated in a mobile phase consisting of 4% aceto-
nitrile in 0.1 M potassium phosphate buffer (pH 2.1).
Statistical Analysis—SigmaStat software (SPSS) was used for all
statistical analyses. The mean values of each treatment group were
subjected to a two-way analysis of variance. When the analysis of
variance was significant (p  0.05), means were compared using Fish-
er’s least significant difference procedure.
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RESULTS
STZ Resulted in Elevated Blood Glucose and Significantly
Less Weight Gain Regardless of RA Treatment—Cumulative
weight gain for diabetic rats was 23 and 36% of respective
non-diabetic values, whereas RA treatment was without effect
(Table I). STZ clearly induced a diabetic state in rats as blood
glucose concentrations were elevated 3.7-fold compared with
control values. Rats treated with RA had no significant effect
on circulating levels of glucose compared with control values,
and RA attenuated the hyperglycemia exhibited by diabetic
rats.
Both Diabetes and RA Treatment Induced Active GNMT—
STZ-treated rats exhibited a 1.9-fold increase in hepatic GNMT
activity compared with the control values (Fig. 1A). RA in-
creased GNMT activity 2.5-fold compared with control rats and
was significantly greater than the degree of induction in STZ-
treated rats. Hepatic GNMT activity was highest in the rats
receiving both STZ and RA (2.6-fold), although this increase
was not significantly different from RA treatment alone. The
changes in GNMT activity in diabetic and RA-treated rats were
also reflected in the abundance of the protein, where a 5.3- and
4.8-fold increase was observed, respectively (Fig. 1B). More-
over, co-administration of STZ and RA significantly induced
GNMT protein abundance (6.8-fold) to a greater extent than
either treatment alone. Thus, both RA treatment and a diabetic
condition modulate the expression of active GNMT in rat liver.
Induction of GNMT by RA and/or DEX was Prevented by
Insulin Treatment—As reported previously (17), both RA and
DEX alone or in co-administration resulted in induction of the
GNMT protein in H4IIE rat hepatoma cells (Fig. 2). Incubating
cells with insulin for 24 h prior to treatment with RA and/or
DEX prevented GNMT induction. Similarly, DEX-mediated in-
duction of GNMT in AR42J cells was also prevented by insulin;
however, RA was not an effective signal to induce GNMT in
these cells.
STZ Treatment Reduced Plasma Homocysteine Concentra-
tions and Induced CBS Abundance—Plasma homocysteine
concentrations were significantly reduced48% in both groups
of STZ-treated rats regardless of RA administration (Fig. 3).
Although we have found previously that RA alone was effective
at lowering circulating homocysteine levels (14), the 26% de-
crease observed under these experimental conditions did not
reach statistical significance. The hypohomocysteinemia exhib-
ited by diabetic rats appears to be due, in part, to a 38%
increase in the abundance of CBS, the initial enzyme in the
irreversible catabolism of homocysteine (Fig. 4). However, CBS
activity is regulated allosterically, and thus flux studies con-
ducted in vivo would be required to evaluate the transsul-
furation pathway. Interestingly, RA treatment of diabetic rats
prevented CBS induction (Fig. 4), even though plasma homo-
cysteine concentrations remained diminished (Fig. 3).
STZ and RA Treatments Differentially Stimulate Homocys-
teine Remethylation Enzymes—In addition to transsulfuration,
the reduced plasma homocysteine levels also appear to reflect
changes in the activity of enzymes involved in homocysteine
remethylation. BHMT activity was significantly increased 3.3-
fold in diabetic rats, whereas the activity of MS was reduced
52% (Table II). RA did not significantly alter either enzyme,
although there was a trend (p  0.061) for increased MS activ-
ity, similar to our previous observations (14). RA was effective
at reducing the activity of BHMT in diabetic rats, but did not
prevent the STZ-mediated decrease in MS activity.
STZ-mediated Elevations in the Hepatic Concentrations of
AdoMet and AdoHcy Were Prevented by RA Treatment—A dia-
betic condition resulted in a significant increase in the hepatic
concentrations of AdoMet (169%) and AdoHcy (90%) (Table III).
Although RA treatment did not significantly alter AdoMet and
TABLE I
Cumulative weight gain and blood glucose concentrations
in rats treated with STZ and/or RA
Values are expressed as mean S.E. (n 6). Values within a column
with different letter superscripts are significantly different, p  0.05.
Weight gain Blood glucose
g mg/dl
Control 77  2a 147  17a
STZ 18  3b 539  19b
RA 73  1a 165  17a
STZ  RA 26  5b 435  51c
FIG. 1. Induction of hepatic GNMT activity and abundance in
STZ-mediated diabetic and RA-treated rats. Diabetic (single dose
of STZ, 60 mg/kg body weight) rats were treated daily with RA (30
mol/kg body weight) for 5 days. Liver samples were removed and the
activity and abundance of GNMT was determined as described under
“Experimental Procedures.” A, GNMT enzyme activity in diabetic and
non-diabetic rats following administration of RA or corn oil. Data are
expressed as means  S.E. (n  6), and bars denoted with different
letters are significantly different (p  0.05). B, GNMT protein abun-
dance in diabetic and non-diabetic rats following administration of RA
or corn oil. A monoclonal GNMT antibody (22) was used for Western
blot analysis, and a representative immunoblot is shown. Data are
expressed as means  S.E. (n  3), and bars denoted with different
letters are significantly different (p  0.05).
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AdoHcy concentrations in non-diabetic rats, it did prevent
their accumulation in diabetic animals. Because AdoMet and
AdoHcy are allosteric regulators of a number of enzymes in-
volved in folate, methyl group, and homocysteine metabolism,
it is difficult to determine the collective metabolic effect of these
changes in diabetic rats in the absence of flux measurements
using isotopic tracers.
DISCUSSION
Methyl groups, homocysteine, and the folate-dependent one-
carbon pool represent interrelated metabolic processes that are
important in health and disease. Because GNMT is a vital
regulatory protein that functions to control the supply and
utilization of methyl groups, it is paramount to understand
how nutritional and/or hormonal factors modulate its expres-
sion. Our earlier work demonstrated that RA and DEX were
independent signals to induce active GNMT in rat liver and in
cultured hepatoma cells (17). Here, we have extended these
findings by demonstrating that a diabetic condition, mediated
by treatment with STZ, also has a profound impact on the
activity of hepatic GNMT. Previous rat studies using alloxan-
induced diabetes reported similar increases (85%) in GNMT
activity (6), whereas treatment with glucagon were less pro-
nounced (23%) (20); however, the mechanistic basis for this
increase in GNMT activity has not been thoroughly explored. A
novel aspect of our studies demonstrates that for both diabetes
and RA, the abundance of GNMT protein was markedly ele-
vated, indicating that GNMT was regulated by transcriptional
and/or translational mechanisms or possibly at the level of
degradation of the protein. It is not known if regulation of
GNMT expression in a diabetic state is the result of an increase
in glucocorticoid levels or a lack of insulin. The cell culture
studies shown here clearly demonstrate that pretreatment
with insulin prevented GNMT induction by both DEX and RA.
It will be important in future studies to more fully characterize
this diabetic condition with alterations in methyl group metab-
olism. Interestingly, the responsiveness of GNMT expression to
RA and DEX appears to be cell type specific. We have found in
other studies that DEX was a more universal signal than RA
for GNMT induction across a number of tissues and cell lines,
including those that do not express detectable GNMT, such as
FIG. 2. Regulation of GNMT expression in rat hepatoma and
pancreatic cell lines. Rat hepatoma H4IIE (upper panel) and pancre-
atic AR42J (lower panel) cells were treated with the following: 0.01%
Me2SO (control, lane 1), 10 M all-trans-retinoic acid (RA, lane 2), 0.1
M dexamethasone (DEX, lane 3), or both RA and DEX (lane 4). A
parallel group of cells was preincubated with 100 nM insulin for 24 h
prior to the respective treatments (lanes 5–8). Following a 72-h incu-
bation period, cells were lysed and used to determine GNMT abundance
via Western blotting as described under “Experimental Procedures.”
FIG. 3. Plasma homocysteine concentrations in STZ-mediated
diabetic and RA-treated rats. Plasma samples from the same rats as
described for Fig. 1 were obtained for the determination of total hom-
ocysteine concentrations by HPLC and fluorometric detection as de-
scribed under “Experimental Procedures.” Data are expressed as
means  S.E. (n  6); bars with different letters are significantly
different (p  0.05).
FIG. 4. The abundance of CBS was elevated in STZ-mediated
diabetic rats and abrogated following treatment with RA. He-
patic tissue samples from the same rats as described for Fig. 1 were
used to determine CBS abundance by Western blot analysis as de-
scribed under “Experimental Procedures.” A representative immuno-
blot is shown above the bar graph. Data are means  S.E. (n  3); bars
denoted with different letters are significantly different (p  0.05).
TABLE II
Activity of remethylation enzymes methionine synthase MS and
BHMT in the livers of rats treated with STZ and/or RA
Values are expressed as mean S.E. (n 6). Values within a column
with different letter superscripts are significantly different, p  0.05.
BHMT MS
units/mg of protein pmol/minmg of protein
Control 40  3a 86  11a
STZ 132  11b 41  5b
RA 51  4a 119  19a
STZ  RA 100  8c 36  6b
TABLE III
Hepatic concentrations of AdoMet and AdoHcy from
rats treated with STZ and/or RA
Values are expressed as mean  S.E. (n  5–6). Values within a
column with different letter superscripts are significantly different, p
0.05.
AdoMet AdoHcy AdoMet/AdoHcy
nmol/g of liver
Control 42.7  2.3a 34.9  2.1a 1.24  0.08a
STZ 114.9  22.5b 66.3  10.2b 1.77  0.34a
RA 38.9  3.1a 34.5  4.1a 1.20  0.15a
STZ  RA 43.6  3.7a 40.3  4.3a 1.14  0.12a
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the human hepatoma cell line HepG2.2
It is not clear how RA, DEX, and/or a diabetic state alter the
expression of GNMT. Previous studies on the regulation of
GNMT activity have found it to be at the posttranslational level
by phosphorylation and allosteric inhibition by 5-CH3-THF (11,
12, 30, 31). Based on the known actions of glucocorticoids and
RA with respect to regulation of gene expression, it is likely
that the induction of GNMT is the result of increased transcrip-
tion. In support of this hypothesis, we have found that pretreat-
ment of hepatoma cells with actinomycin D prevented GNMT
induction by DEX and RA, and abundance of the protein ap-
pears to reflect changes in its synthesis rate.3 However, GNMT
has not been reported to contain a retinoic acid- nor a glucocor-
ticoid-response element in its promoter region (32). Therefore,
it is likely that additional intracellular signals are required to
directly mediate regulation of GNMT expression. Nonetheless,
we cannot exclude the possibility that increases in phosphoryl-
ation of the protein have a role in increasing GNMT activity,
particularly as glucagon and glucocorticoids can exert their
action via alterations in protein kinase activity.
Homocysteine concentrations reflect the collective balance
between production from AdoMet-dependent transmethylation
reactions, remethylation to methionine, and catabolism via the
transsulfuration pathway. As has been reported (19, 20), we
also found that a diabetic state was characterized by a reduc-
tion in circulating homocysteine levels. This change in homo-
cysteine homeostasis appears to reflect an increase in the ac-
tivity of BHMT and the abundance of CBS, even though the
activity of MS was reduced. Similarly, previous diabetes/hyper-
glucagonemia studies have attributed the hypohomocysteine-
mia to up-regulation of CBS and -cystathionase, whereas the
activity of hepatic BHMT andMS were not significantly altered
(19–21). However, in the absence of flux studies it is difficult to
determine homocysteine catabolism because CBS is regulated
allosterically by other factors such as AdoMet, a known allo-
steric stimulator of CBS activity (33). In support of the increase
in CBS abundance that we reported, we also found that the
hepatic concentration of AdoMet was elevated in agreement
with previous studies using hyperglucogonemic rats (20). Ele-
vations in hepatic AdoMet levels may be the result of increased
expression of methionine adenosyltransferase, as it is up-reg-
ulated by glucocorticoids (34). An increase in hepatic AdoMet
concentrations would also be expected to reduce 5-CH3-THF
levels as a result of allosteric inhibition of 5,10-methylenetet-
rahydrofolate reductase (9, 10). The lack of 5-CH3-THF acting
as an inhibitory ligand for GNMT (11), like phosphorylation,
may be a contributing factor for the increase in its activity in
diabetic rats. An interesting aspect of our work was that the
administration of RA to diabetic rats prevented CBS induction
and AdoMet accumulation and partially reduced the activity of
BHMT, whereas MS activity was unaffected. In contrast to
diabetes, RA alone had no affect on CBS abundance or the
activity of BHMT and MS, although we have found in previous
studies that RA does increase MS when provided for a longer
period of time (14). However, it should be noted that the activ-
ity and abundance of GNMT remained elevated in rats treated
with RA. This further illustrates the need for metabolic flux
measurements under in vivo conditions to determine the out-
come of these interactions.
The implications of these results for humans are profound, as
diabetes and its complications are a significant health problem
and the use of pharmacological retinoid compounds has risen
dramatically in recent years (35). In addition to folate, optimal
metabolism of methyl groups and homocysteine is dependent
on a number of B-vitamins including B12, B6, and riboflavin, as
well as an adequate source of methyl groups such as methio-
nine and choline. Moreover, it is well known that the human
population has a significant prevalence of polymorphic en-
zymes important in methyl group, homocysteine, and folate-de-
pendent one-carbon metabolism (36). Taken together, these
nutritional, genetic, and hormonal factors underscore the need
for understanding the relationship between these metabolic
pathways and diabetes. As most type I diabetics control their
disease by the use of insulin, there are nonetheless likely many
individuals who do not adequately monitor their condition.
Moreover, many of the changes noted in our study were re-
cently demonstrated in a type II diabetes (Zucker diabetic fatty
rat) model, including an increase in hepatic CBS, BHMT, and
AdoMet (37).
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